tetra bio-pharma investor presentation

OCTOBER 2016

ForewordlookingStatements

Thispresentationcontainscertainforward-lookingstatementsthatmayinvolveanumberofrisksanduncertainties.ActualeventsorresultscoulddiffermateriallyfromtheexpectationsandprojectionsofArcScanInc..TheinformationcontainedinthispresentationhasnotbeenapprovedordisapprovedbyanySecuritiesCommissioninCanada,TheSecuritiesandExchangeCommissionintheUSorotherregulatorybody.ExceptforstatementsofhistoricalfactrelatingtotheCompany,certaininformationcontainedhereinconstitutes"forward-lookingstatements".Forward-lookingstatementsarefrequentlycharacterizedbywordssuchas"plan","expect","project","intend","believe","anticipate"andothersimilarwords,orstatementsthatcertaineventsorconditions"may"or"will"occur.

Forward-lookingstatementsarebasedontheopinionsandestimatesofmanagementatthedatethestatementsaremade,andaresubjecttoavarietyofrisksanduncertaintiesandotherfactorsthatcouldcauseactualeventsorresultstodiffermateriallyfromthoseprojectedintheforward-lookingstatements.ThesefactorsincludetheinherentrisksinvolvedinthedevelopmentofbotanicalbasedpharmaceuticalsormedicaldevicesregulatedbyHealthCanada,theFDAorotherinternationalregulatoryagencies,productobsolescence,theuncertaintiesinvolvedinpatentdefenseandcomplexitiesandtimelinesassociatedwithproductapprovalsinmultiplejurisdictions.

Thepossibilityofprojectcostoverrunsorunanticipatedcostsandexpenses,uncertaintiesrelatingtotheavailabilityandcostsoffinancingneededinthefutureandotherfactors.Circumstancesormanagement'sestimatesoropinionscouldchange.Thereaderiscautionednottoplaceunduerelianceonforward-lookingstatements.Exceptasrequiredbylaw,weundertakenoobligationtoupdateorrevisepubliclyanyforward-lookingstatements,whetherasaresultofnewinformation,futureeventorotherwise,afterthedateonwhichthestatementsaremadeortoreflecttheoccurrenceofunanticipatedevents.Neitherwenoranyofourrepresentativesmakeanyrepresentationorwarranty,expressorimplied,astotheaccuracy,sufficiencyorcompletenessoftheinformationinthispresentation.Neitherwenoranyofourrepresentativesshallhaveanyliabilitywhatsoever,undercontract,tort,trustorotherwise,toyouoranypersonresultingfromtheuseoftheinformationinthispresentationbyyouoranyofyourrepresentativesorfromomissionsfromtheinformationinthispresentation.

InnovationsinthePharmaseuticalizationandNeutraseuticalizationofMedicalCannabis

REPORT:TheCannabisBiotech/PharmaMarketCouldSurpass$20Billionby2020ViridianCapitalAdvisors|Wednesday,02December201505:43 (EST)

THEPHARMACEUTICALAPPROACHTOCANNABISRESEARCHANDMEDICALINNOVATION

APhysician’sdecisiontoprescribeanewdrugorevenanaturalhealthproducthastobebasedonEvidence-BasedMedicine– Alegalandethicalrequirement.

§ Currently,nobodyofevidenceexiststonotsupporttheprescriptionorrecommendationofmedicalmarijuanainanymedicalcondition,includingterminalcancer.AccordingtoCanadianandUSAdrugregulatoryagencies,theisnoevidencetosupportthesafetyandefficacyofmarijuanaforuseinthetreatmentofpainoranyotherindication.

§ TBPproductdevelopmentplanwouldprovidethedatanecessaryfordrugregulatoryagenciestograntmarketingapprovalandphysicianstoprescribeorrecommendourproducts.

§ Ascannabisbecomeslegalisedacrosstheglobethemedicalandscientificcommunitywouldstillrequirepharmaceuticalconsumerdrugproductsdevelopedwithproperresearch,dataandprotocol.InsurancecompanieswillonlybeabletocoverthecostofproductswithDrugIdentificationNumbers.

§ TBPtakesthenaturalaspectsofmedicalcannabisandappliesthescienceofpharmatodevelopproductsthatpatientswant,doctorswanttoprescribeandinsurancecompanieswillcover.

TBPProductPipelineTBPinvestssignificanttimeandcapitalintoacontinuousandsustainablepipelineofproductsbasedonpatientneedsanddrivenbyscientificRandD

PrescriptionDrugs

§ PPP001*:§ bringing‘smoked’marijuanatopatients.

§ PPP002:§ Insomniaacomorbidityinchronicpainpatients.§ Botanicaldrugtoincreasequalitysleepinpatientssufferingfromchronicpain.

§ PPP003*:§ Combinationproduct– oraladministration.§ Chronicpain,PTSDandotherneurologicandpsychiatricconditions.§ CompeteagainstGWwithproprietaryextracts.

§ PTGR*:§ Topicalprescriptiondrugforpainmanagement.

§ R&D*§ togeneratepipeline(createIPanddisease-specifictreatments).

*cannabissativabasedproducts.

24MonthProjectedMilestones

Partners

AlgorithmePharmaisconductingstage1clinicaltrialsofPP001incollaborationwithPhytoPainPharma

McGillUniversityiscollaboratingwithAgrotekandGrowProsonanNSERCfundedresearchstudytodevelopconsumerproductscontainingcannabinoids.

AphriaisapublicallytradedproducerofMedicinalCannabisunderlicensefromtheCanadianFederalGovernment.AphriahaspartneredwithPPPfortheproductionofCannabisforuseinPP001.

TheNationalSciencesandEngineeringResearchCouncilofCanadaconnectsindustrywithworld-firstsinknowledgeandthepeoplebehindthem,fuelingR&Dandleadingtofirstsinthemarketplace.TheyhavegrantedTBPsubsidiaryGrowProsCannabiswithresearchfundingrelatedtothedevelopmentofConsumerproductsincollaborationwiththeuniversityofMcGill.

NaturalHealthProductStrategy

§ Alongwithmedicinalandrecreationalcannabis,naturalhealthproductscontainingnonpsychoactivecannabinoidssuchasCannibidiol(CBD)arewidelygainingpopularityparticularlyintheUnitedStateswheremorefavorableCBDregulationsexist.

§ AgroTekintendstoacquireformulationsandestablishedbrandswiththegoalofintegratingourCannabisR&DintothelessregulatedNHPmarket

Theestimatedsizeofthe2015hempCBDbasedpersonalcareproducts($147million).Thismarksanestimated10%increaseover2014,

anddoesn’tevenincludesalesdatafrombigboxretailers,whichcouldmorethandoubletheestimate.*

*MMJ.com

OvertheCounterNHPPipeLine§ AGT001*:

§ Topicalproductforpainmanagement.

§ AGT002productline-oral*:§ Cardiovasculardiseaseprevention,

athleticperformance,andwell-being.

§ AGT003productline*:§ Topicalproductsforskincare.

§ AGT004*:§ Topicalforwomen- qualityoflife.

§ R&D*:§ CreateIPandpipelineforsupplement

healthcaremarket.

*cannabissativabasedproducts(mayormaynotcontainpsychoactiveingredients)TargetingbothCanadaandUSAsupplement(OTC)markets.

Cannabis/MedicinalPlantcultivationandsourcing

• OriginallyappliedforACMPRlicenseinNovemberof2014,Currentlyinstage3/5

• Ownsaleaseoptionon190acresofagriculturalland45minnorthofOttawa

• Signedaco-opagreementwithDelta9Biotechtocollaborateonlicensingofthefacility

• CurrentlyexaminingalternativelicensingoptionsforPharmaDevelopmentandsourcinglegalsupplyforuseinPharmaandNHPproducts

CurrentMarketValuation~13MValue Total

CommonShares 82.61MWarrantsexp09/28/18 .07-.15 20.7MCompensationWarrants .05 1.5MOPTIONSexp11/5/17 .05-.32 6.3MAveragePriceofWarrants: $0.11AveragePriceofOptions: $0.05

TotalProceedsfromWarrantsandoptions$2.224M

CapitalStructure(asofOct5,2016)

CompetitiveLandscapeGWPharma$GWPHMarketCapitalization:$3.33BUSDGWPharmahas2productsinitspipelineinstage1andstage3forepilepsyandMS.

CannabisScienceInc.$CBISMarketCapitalization$47.22MUSDConductsqualitativeresearchonmedicinalcannabisinanonpharmaceuticalmanor.TheyhavenoproductsinClinicalTesting

INSYSTherapeuticsinc- $INSYMarketCapitalization$810.5MUSDIsatraditionalPharmacompanythatwasawardedorgandrugstatusforCBDfortreatmentofGBM.Theydonothaveanycurrentclinicaltrials

ZynerbaPharmaceuticals$ZYNE-MarketCapitalization$101MUSDDevelopingasyntheticTHCtransdermalpatchaswellasasyntheticCBDgel

CaraTherapeuticsInc.$CARAMarketCapitalization$214.2MR&DonCannabinoidpreceptors.Utilizingsyntheticcompounds

Financing

• Jan15- Oct16Raised~$1.4Mthroughprivateplacementsandexecutedwarrantsat.025-.05-.10-.15

• October2016Secured2MequitylineofCreditfromNYCprivateequityfirmAluminaPartners

• November2016Closeda$914,000financingroundat.15withafull12monthwarrantat.20

Leadership

Operations

• AndreRancourt – ChiefExecutiveOfficer• GuyChamberland,PHD– ChiefScientificofficer• SabinoDiPaola – ChiefFinancialofficer• RyanBrown – VPbusinessdevelopmentandcommunications• RandyRinguette,PHD–MedicalResearcher• CharlesCampbell,PHD–MedicalResearcher

BoardofDirectors

• AndreAudet – Chairman/Director• AndreRancourt – Director• BenoitChotard – Director• RobertBrouilette – Director

Contacts

+ investors@tetrabiopharma.com

+ ryan@tetrabiopharma.com

+ www.tetrabiopharma.com